Optimi Health plans a Health Canada-authorized psilocybin trial for major depressive disorder, a condition affecting an estimated 332 million people worldwide. For investors, the study represents an initial move toward potential registration, with Optimi supplying its own natural psilocybin and retaining exclusive ownership of the results.

Key Highlights

  • Health Canada has authorized Optimi Health’s clinical trial to proceed.
  • Optimi Health plans to manufacture the study’s natural psilocybin at its GMP Facility and retain exclusive ownership of the results.
  • Health Canada authorized the multisite Canadian study to proceed.
  • The study will assess the safety and efficacy of one supervised dose of naturally derived psilocybin in people with major depressive disorder.

Health Canada Authorizes Psilocybin Study The

Health Canada has authorized the trial to proceed. multisite Canadian study will assess the safety and efficacy of one supervised dose of naturally derived psilocybin in people with major depressive disorder. Optimi (NASDAQ: OPTH) said it will provide psilocybin produced at its GMP facility in British Columbia. The company will hold exclusive ownership of the clinical results. The study is intended to rank among the largest investigations of naturally derived psilocybin to date.

Trial Marks Potential Registration Step Optimi

described the study as an initial step toward potential registration as it expands into clinical drug development. The company said current cash on hand can fund the trial. Interim safety and efficacy updates are planned, while full topline results are expected after dosing and follow-up evaluations are completed for all participants.